IMPEDIMED LIMITED — Board/Management Information 2017

Mar 19, 2017

==> picture [226 x 43] intentionally omitted <==

20 March 2017

ASX ANNOUNCEMENT

IMPEDIMED ANNOUNCES BOARD OF DIRECTORS APPOINTMENTS

Brisbane, Australia, Carlsbad, Calif., and Bloomington, Minn. - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, is pleased to announce the appointment of two non-executive Directors, Mr Amit Patel and Mr Donald (Don) Williams.

Mr Williams has more than 35 years of senior business leadership as a Certified Public Accountant (CPA) and an accredited company Director. He brings a depth of experience in the medical devices and life sciences industries, with a focus on helping companies execute on their growth strategies, with experience across many aspects of operations and financing. He has been an advisor on a number of initial public offerings, secondary offerings, private and public debt financings, as well as numerous mergers and acquisitions.

He is currently a Director and Chair of the Audit Committee of NASDAQ listed companies Akari Therapeutics (AKTX); Alphatec Holdings Inc. (ATEC); and Marina Biotech Inc. (MRNA). He is also on the board of Proove Biosciences Inc., a privately held company.

Mr Williams was previously an Audit Partner and National Leader of Grant Thornton LLP’s Life Sciences practice. Prior to this, he spent 26 years with Ernst and Young LLP. This tenure included six years as the Leader of the Pacific Southwest Strategic Growth Markets and Venture Capital Advisory Group.

Mr Patel is an expert in digital health, with a depth of experience in commercializing technologies across the software and healthcare industries. He is currently the CEO and Co-Founder of Vios Medical, which has developed an FDA cleared Internet of Things (IoT) based patient management platform used across major hospitals in the US and India. He has held a number of senior roles in healthcare and medtech companies, including Medtronic. Mr Patel holds an MBA from Stanford University Graduate School of Business and a Bachelor of Biomedical Engineering from University of Minnesota – Twin Cities.

Dr Cherrell Hirst, AO, Chair of ImpediMed said: “On behalf of my fellow Board members I am pleased to welcome both Amit and Don to the ImpediMed board. Each brings distinctive skills that will serve the company well as we continue to grow and establish our leadership in digital healthcare.”

“These new appointments are part of an ongoing plan to expand and evolve the skills within the Board. Commensurate with our growth and rapid progress of our next generation device and expansion into chronic heart failure, we are expanding the breadth of experience within the board, and increasing the number of Directors on the Board to six. We are also in the final stages of hiring an additional Australian based Director.”

Cherrell Hirst AO Chairman

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

Media Contact:

Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men. For more information, visit www.impedimed.com.